Healthcare companies struggle with staff vaccination mandates

Several studies reveal that a significant portion of the healthcare workforce has some qualms about getting a Covid-19 vaccine, and healthcare companies are struggling with the decision to mandate vaccinations for their staff.

That’s according to a recent report from The Washington Post, which dived into the nitty-gritty of requiring coronavirus shots.

March 1 marked the first time a senior care facility required its staffer get the COVID-19 vaccine, but more such facilities and healthcare operators are likely to follow. The decision, which was made by Virginia-based Silverado, likely caused some friction and set off alarm bells elsewhere, as a portion of healthcare workers have noted they oppose such mandates.

Last month, a survey of healthcare workers from The Post and the Kaiser Family Foundation found as many as 1 in 3 healthcare workers say they were skeptical of the COVID-19 vaccines currently available. There are three vaccines available in the U.S.––from Pfizer, Moderna-BioNTech and Johnson & Johnson. 

The question of whether healthcare facilities should require vaccination for their workers is a tricky one, although more are cracking down. The Houston Methodist health system recently required its staff to receive at least one dose of a vaccine-–or risk being laid off, The Post reported.

See the full story below:

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.